Genmab — Januar 2020

[StockBull]

Det var rettidig omhu

[E_L]

Daratumumab in untreated newly diagnosed multiple myeloma https://journals.sagepub.com/doi/10.1177/2040620719894871

[E_L]

interesting to see how authors ( Shaji K. Kumar ) do not even talk about the shorter infusion time for the subcutaneous formulation of daratumumab but about the decrease in toxicity "A subcutaneous formulation of daratumumab has been introduced to decrease the risk of infusion reactions...."

[JKY_VH]

Mcj, tror du har lavet en John Faxe 26.6.92, tlk med det:-)

[Mcjean]

Ja den er pænt ramt, men set i et økonomiske perspektiv kan det vidst ikke sammenlignes:-)

[JKY_VH]

enig

[Riis7]

er 1412 nu os bunden;-)

[NWulff]

E L, not really sure why reduced infusion time should be relevant in a Review focusing on Daratumumab in untreated NDMM patients?

[E_L]

it is relevant for the subcutaneous formulation. We all want SC for the shorter infusion /treatment time ; they point at the importance of the decrease of infusion reactions with SC

[JKY_VH]

Det ved ingen Riis7, men købere i det prisleje har da haft mulighed for at realisere en gevinst.

[Bulder]

Particularly for ND pts convenience is important. The more sick you get, the less important.

[bibob]

Ja, det gik jo nogenlunde i dag.

[lahn1]

Virkelig Bulder - troede det var lige omvendt

[Plimsoller]

God morgen

[bibob]

God morgen.

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

Canada CADTH has issued an initial Reimbursement recommendation for #Daratumumab combination (DRd) https://twitter.com/CADTH_ACMTS/status/1214683188615942144 https://cadth.ca/daratumumab-darzalex-multiple-myeloma?utm_source=CONS+List&utm_campaign=487fd1698e-pCODR-08-01-2019-Keytruda-int-pt_COPY_01&utm_medium=email&utm_term=0_f3b3313866-487fd1698e-263130189

[NWulff]

Still why is it relevant in a Review? It is relevant to the patient, in marketing and otherwise in accessing toxicity. Thus time is not of essence in a Review like that. The original literature likely have commented on the matter. If I were ask to peer-review this review I would have had it removed by the authors if they started talking about convenience for patients
.

[Bulder]

yes, you are right